Nivolumab Active in Squamous Cell Carcinoma of the Anal Canal
Nivolumab was clinically active and well-tolerated among patients with treatment-refractory metastatic squamous cell carcinoma of the anal canal (SCCA).
Nivolumab was clinically active and well-tolerated among patients with treatment-refractory metastatic squamous cell carcinoma of the anal canal (SCCA).
Addition of cetuximab to definitive chemoradiation (CRT) reduces locoregional failure rates but is associated with grade 4 toxicity.
Care at radiation oncology centers with a higher volume is associated with improved survival among patients with squamous cell carcinoma of the anal canal.
Researchers argue that combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated across cancer types.
Incidence rates (IRs) of anal squamous cell carcinoma (SCC) and squamous carcinoma in situ (CIS) have significantly increased overtime.
Human papillomavirus (HPV) type 16 (HPV16) seropositivity is relatively common before anal cancer diagnosis.
The FDA has approved Gardasil 9 (9-valent human papillomavirus types) vaccine for the prevention of cervical, vulvar, vaginal, anal cancers.
Results of ADXS-HPV with standard chemo and radiotherapy for HPV-associated anal cancer who have a high risk of recurrence.
[Clin Med Insights Oncol] HPV is a risk factor for anal intraepithelial neoplasia (AIN). Etiology, anatomy, pathogenesis, management of squamous cell carcinoma (SCC) discussed.
Increased screening and changing demographics may explain the sharp rise in cases of squamous cell carcinoma of the anal canal and anal carcinoma in situ.